Abstract: An incubator system configured to illuminate at least one or more cell culture chamber devices and to rotate them about a respective predetermined axis, each cell culture chamber device comprising an enclosure, the enclosure configured to contain a cell culture media, and at least one viewing area configured to allow inspection of at least a part of the cell culture media, the incubator system further comprising at least one illumination device and at least one monitoring device, the at least one monitoring device configured to provide one or more monitoring signals of at least part of an illuminated cell culture media or an illuminated cell culture chamber, illuminated, by at least one of the at least one illumination device, with a signal of electromagnetic radiation, preferably incoherent or coherent ultraviolet, visible, infrared, and/or near-infrared light of broad or narrow wavelength spectrum, and wherein the incubator system further comprises or is in connection with one or more processing units confi

Abstract: An incubator configured to receive a predetermined number of cell culture chamber devices, each cell culture chamber device including an enclosure configured to contain a cell culture media. The incubator has a housing including an incubation chamber configured to contain at least a respective part of the cell culture chamber devices when received by the incubator, and at least one registration and/or detection device being integrated with the incubator and being configured to register and/or detect an illumination or visualisation signal after passing, reflecting, or propagating through at least a part of the enclosure of at least one of the predetermined number of cell culture chamber devices when received by the incubator.

Abstract: A cell culture chamber device for growing cell cultures and tissues. The device includes: an enclosure containing a cell culture media, the enclosure being defined partly by a first end, a second end, and a connecting wall. The first end or a part or window thereof is substantially transparent, and the second end and/or the connecting wall, or a respective part or window thereof, is/are substantially transparent/translucent. The first end is configured to be optically aligned, at least for some period of time or periodically, with the second end and/or with the connecting wall so that light or another illumination or visualisation signal, transmitted through or by the second end and/or through or by the connecting wall into the enclosure is transmitted through the cell culture media and out through the first end to outside the enclosure, and e.g. to outside the cell culture chamber device.

Abstract: The invention relates to a bioreactor (10, 10?, 100) adapted for rotation, the bioreactor comprising: a vessel (12) comprising: a first end (24) and a second end (26) which define a central axis (28) of the vessel (12) extending along a first direction, e.g. a length direction, of the vessel (12) from said first (24) to said second end (26), at least one wall (18, 18?, 20) running along the first direction of the vessel (12), at least one media conduit (22, 22?) defining a volume for receiving fresh or spent media; an inner chamber defined by at least a part of a space confined within said at least one wall (18, 18?, 20) and comprising a fresh media chamber (14) and a spent media chamber (16); a cell culture chamber (30) in fluid communication with said at least one media conduit (22, 22?) and said fresh (14) and/or spent media chamber (16); and a movable wall (38) configured, within said inner chamber, to separate said fresh media chamber (14) from said spent media chamber (16) within said inner chamber.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: There is provided a bioreactor which is provided with a lid (13) that facilitates access to the incubation cavity. Specifically the end wall of the incubation cavity is constituted by the lid (13) so that removal of the cap renders the incubation cavity fully accessible.

Abstract: A bioreactor or culture vessel for incubation of one or more cell cultures, tissue biopsies, cell clusters, tissue-like structures, “prototissues” or similar samples is described. The bioreactor comprises an incubation chamber, a liquid reservoir and conduction means separated from each other by semipermeable membranes. Specifically, the invention provides a humidity chamber design which simplifies the construction of the bioreactor.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an anti-diabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos (Aspalathus spp.), aspalathin as such or in combination with rutin.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: A bioreactor or culture vessel for incubation of one or more cell cultures, tissue biopsies, cell clusters, tissue-like structures, “prototissues” or similar samples. The bioreactor comprises an incubation chamber, a liquid reservoir and conduction means separated from each other by semipermeable membranes. Specifically, the invention provides a humidity chamber design which simplifies the construction of the bioreactor.

Abstract: There is provided a bioreactor which is provided with a lid (13) that facilitates access to the incubation cavity. Specifically the end wall of the incubation cavity is constituted by the lid (13) so that removal of the cap renders the incubation cavity fully accessible.

Abstract: Novel and useful compositions derived from honeybush plant extract for treating diabetes are provided. It has been found that the plant extract of the present invention exhibit a superior antidiabetic effect when administered in an amount from about 1 milligram to about 5 milligrams, preferably to about 2.5 milligrams, per kilogram body weight.

Abstract: Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an antidiabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos (Aspalathus spp.), aspalathin as such or in combination with rutin.

Abstract: Novel and useful compositions derived from honeybush plant extract for treating diabetes are provided. It has been found that the plant extract of the present invention exhibit a superior antidiabetic effect when administered in an amount from about 1 milligram to about 5 milligrams, preferably to about 2.5 milligrams, per kilogram body weight.

Abstract: The present invention provides a bioreacto 1r for incubation of cell cultures, tissue biopsies, cell clusters, tissue-like structures, ‘prototissues’ or similar samples. The bioreactor is generally adapted for rotation for use in microgravity conditions and equipped with an incubation cavity having a small internal fluid volume, generally less than 1 ml. To avoid problems associated with small volume incubation, the bioreactor may include a humidity chamber or other means of avoiding dehydration as well as substantially fluid-tight closures for access ports that avoid introduction of air bubbles to the incubation cavity. The small-volume bioreactor permits long term maintenance of tissue differentiation states in cultures. Also provided are methods of incubating cells or tissues using the bioreactor including methods of creating molecular profiles of biological effects of chemical compositions on differentiated cell or tissue samples maintained in long term culture.

Abstract: Provided herein are human proteins or xenogeneic homologs thereof, which are predictive markers for acute allograft rejection, processes for obtaining the proteins of the invention, nucleotide sequences which encode the proteins, and antibodies to the proteins. Also provided are methods of assaying biological samples for the presence, and optionally the amounts of proteins of the invention, a kit for assaying such proteins in a bodily sample, and a method and kit related to diagnosis and prognosis of organ rejection in a subject.